Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.39 |
| ▸ | PPARA | Q07869 | 12/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292884 | 0.82 | NR3C1 (0.38) | PPARGPPARANPC1RAB9ANR3C1 | |
| SCHEMBL292886 | 0.78 | NR3C1 (0.45) | PPARGPPARANR3C1PGRNR3C2 | |
| SCHEMBL6807534 | 0.76 | CNR2 (0.37) | NPC1RAB9A | |
| SCHEMBL13754566 | 0.71 | NR3C1 (0.66) | PPARGPPARANR3C1PGRNR3C2 | |
| SCHEMBL675882 | 0.71 | NR3C1 (0.66) | PPARGPPARANR3C1PGRNR3C2 | |
| SCHEMBL447350 | 0.71 | NR3C1 (0.66) | PPARGPPARANR3C1PGRNR3C2 | |
| SCHEMBL8594784 | 0.63 | NPC1 (0.50) | PPARGPPARANPC1RAB9ALMNA | |
| SCHEMBL8594782 | 0.63 | NPC1 (0.50) | PPARGPPARANPC1RAB9ALMNA | |
| SCHEMBL292067 | 0.62 | NR3C1 (0.43) | NR3C1PGRNR3C2 | |
| SCHEMBL19733323 | 0.62 | L3MBTL1 (0.71) | PPARGPPARANPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049112-B1 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB (US) | 2012-03-14 | — | — | EP | disclosed |